×
About 736 results

ALLMedicine™ Acquired Thrombotic Thrombocytopenic Purpura Center

Research & Reviews  325 results

Acquired Thrombotic Thrombocytopenic Purpura in a 5-Year-Old Child With Wiskott-Aldrich...
https://doi.org/10.1097/MPH.0000000000002150
Journal of Pediatric Hematology/oncology; Özdemir Ö, Orhan MF et. al.

Mar 26th, 2021 - Thrombocytopenia is often seen as a laboratory finding during childhood. A supposed idiopathic thrombocytopenic purpura patient who was later diagnosed as Wiskott-Aldrich syndrome (WAS) and developed acquired thrombotic thrombocytopenic purpura (a...

Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in...
https://doi.org/10.1002/pbc.28949
Pediatric Blood & Cancer; Siddiqui A, Journeycake JM et. al.

Mar 4th, 2021 - We describe how infants and children with hereditary and acquired autoimmune thrombotic thrombocytopenic purpura (TTP) initially present and how they can be promptly diagnosed and effectively managed. These are uncommon disorders that are commonly...

Application of the French TMA Reference Center Score and the mortality in TTP Score in ...
https://doi.org/10.1002/jca.21880
Journal of Clinical Apheresis; Domingo-González A, Regalado-Artamendi I et. al.

Feb 3rd, 2021 - Acquired thrombotic thrombocytopenic purpura (aTTP) is still associated with a 10% to 20% death rate and its clinical course is characterized by recurrent episodes in up to 50% of cases. Over the last decade, mortality predicting models like the F...

The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura cont...
https://doi.org/10.1182/blood-2014-04-561142
Bone Marrow Transplantation; Schaller M, Vogel M et. al.

Feb 2nd, 2021 - Acquired thrombotic thrombocytopenic purpura (TTP) is the consequence of a severe ADAMTS13 deficiency resulting from autoantibodies inhibiting ADAMTS13 or accelerating its clearance. Despite the success of plasma exchange the risk of relapse is hi...

Acquired Thrombotic Thrombocytopenic Purpura Associated with Acute Hepatitis A Infection.
https://doi.org/10.1016/j.amjmed.2020.10.045
The American Journal of Medicine; Montgomery CD, Hall EJ et. al.

Dec 14th, 2020 - Acquired Thrombotic Thrombocytopenic Purpura Associated with Acute Hepatitis A Infection.|2020|Montgomery CD,Hall EJ,Pellegrino R,Yakes EA,Green JR,|

see more →

Guidelines  5 results

CABLIVI (caplacizumab-yhdp) Prescribing Information
http://products.sanofi.us/cablivi/cablivi.pdf

Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

FDA approves Cablivi, first treatment for acquired thrombotic thrombocytopenic purpura
https://www.healio.com/hematology-oncology/hematology/news/online/%7Be91d83f6-8859-412b-970c-198151f0b208%7D/fda-approves-cablivi-first-treatment-for-acquired-thrombotic-thrombocytopenic-purpura
Pazdur,R.

Feb 5th, 2019 - The FDA today approved caplacizumab-yhdp injection as the first therapy specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting disorder.

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the firs...

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
https://www.nejm.org/doi/10.1056/NEJMoa1806311
Scully,M.,et al

Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which re...

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
https://www.jwatch.org/na48305/2019/01/17/caplacizumab-acquired-thrombotic-thrombocytopenic-purpura
Green,David

Jan 16th, 2019 - Patients with acquired thrombotic thrombocytopenic purpura (TTP) have von Willebrand factor (VWF)–mediated platelet aggregates that ...HERCULES Trial

see more →

Drugs  4 results see all →

Clinicaltrials.gov  349 results

Acquired Thrombotic Thrombocytopenic Purpura in a 5-Year-Old Child With Wiskott-Aldrich...
https://doi.org/10.1097/MPH.0000000000002150
Journal of Pediatric Hematology/oncology; Özdemir Ö, Orhan MF et. al.

Mar 26th, 2021 - Thrombocytopenia is often seen as a laboratory finding during childhood. A supposed idiopathic thrombocytopenic purpura patient who was later diagnosed as Wiskott-Aldrich syndrome (WAS) and developed acquired thrombotic thrombocytopenic purpura (a...

Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in...
https://doi.org/10.1002/pbc.28949
Pediatric Blood & Cancer; Siddiqui A, Journeycake JM et. al.

Mar 4th, 2021 - We describe how infants and children with hereditary and acquired autoimmune thrombotic thrombocytopenic purpura (TTP) initially present and how they can be promptly diagnosed and effectively managed. These are uncommon disorders that are commonly...

Application of the French TMA Reference Center Score and the mortality in TTP Score in ...
https://doi.org/10.1002/jca.21880
Journal of Clinical Apheresis; Domingo-González A, Regalado-Artamendi I et. al.

Feb 3rd, 2021 - Acquired thrombotic thrombocytopenic purpura (aTTP) is still associated with a 10% to 20% death rate and its clinical course is characterized by recurrent episodes in up to 50% of cases. Over the last decade, mortality predicting models like the F...

The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura cont...
https://doi.org/10.1182/blood-2014-04-561142
Bone Marrow Transplantation; Schaller M, Vogel M et. al.

Feb 2nd, 2021 - Acquired thrombotic thrombocytopenic purpura (TTP) is the consequence of a severe ADAMTS13 deficiency resulting from autoantibodies inhibiting ADAMTS13 or accelerating its clearance. Despite the success of plasma exchange the risk of relapse is hi...

Acquired Thrombotic Thrombocytopenic Purpura Associated with Acute Hepatitis A Infection.
https://doi.org/10.1016/j.amjmed.2020.10.045
The American Journal of Medicine; Montgomery CD, Hall EJ et. al.

Dec 14th, 2020 - Acquired Thrombotic Thrombocytopenic Purpura Associated with Acute Hepatitis A Infection.|2020|Montgomery CD,Hall EJ,Pellegrino R,Yakes EA,Green JR,|

see more →

News  53 results

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 15th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

A new era of TTP treatment
https://www.mdedge.com/hematology-oncology/article/196522/bleeding-disorders/new-era-ttp-treatment?channel=41022
Kristin S. Ricci, MD

Mar 18th, 2019 - Earlier this year, the Food and Drug Administration approved Cablivi (caplacizumab-yhdp) (Sanofi Genzyme, Cambridge, Mass. ) for the treatment of acquired thrombotic thrombocytopenic purpura (TTP), making it the first medication specifically indica.

Edible Weed Triggers MI; A Heart-Shaped Question; Pivotal Year for PCSK9s
https://www.medpagetoday.com/cardiology/prevention/78063

Feb 18th, 2019 - A marijuana lollipop apparently triggered a heart attack in a 70-year-old man with stable coronary artery disease hoping for pain relief and better sleep. (Canadian Journal of Cardiology) The FDA approved caplacizumab-yhdp (Cablivi) as the first t...

FDA approves caplacizumab for aTTP
https://www.mdedge.com/clinicianreviews/article/194030/bleeding-disorders/fda-approves-caplacizumab-attp?channel=27979
Jennifer Smith

Feb 6th, 2019 - The Food and Drug Administration has approved caplacizumab (Cablivi) in combination with plasma exchange and immunosuppressive therapy for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab is an anti–vo.

Acquired TTP Drug Wins Approval
https://www.medpagetoday.com/hematologyoncology/hematology/77859

Feb 5th, 2019 - WASHINGTON -- Caplacizumab (Cablivi), an antibody drug targeting von Willebrand factor, is now approved for acquired thrombotic thrombocytopenic purpura (aTTP), the FDA said Wednesday. The drug is to be given in combination with plasma exchange an...

see more →